
Since the 1990s, CD3 monoclonal antibody has been used in CIK cell therapy to stimulates the proliferation and activation of T cells. Under the cooperation of other cytokines, such as IL2 and IL1a, CIK cells with rapid proliferation, high tumoricidal activity, broad tumor killing spectrum and non-MHC-restricted tumor killing characteristics are generated, which has significant effects on the treatment of cancer, chronic leukemia, liver disease and neurological diseases. Obviously, It is necessary to control the residues of raw materials in the final cell therapy product.
Vyberte, čo potrebujete, a my sa vám ozveme
WIKIS pribudajucim vekom sa zvysuje riziko vzniku mnohych ochoreni. Okrem zmien sposobenych prirodzenym ...
Čítať viac
WIKIV mnohých médiách čoraz častejšie počujeme o autoimunitných ochoreniach alebo o samotnej autoimunite...
Čítať viac
WIKIS prichodom leta zacina kvitnut mnozstvo rastlin. Pocet pelovych zrn vo vzduchu sa zvysuje a vcely i...
Čítať viac